Novabay Pharmaceuticals (NBY) Stock Price, Quote & News

Company Profile

NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 510 899 8800

Fax: 510 474 1577

Website: novabay.com

Address:

2000 Powell Street, Suite 1150, eleventh floor, Emeryville, United States

Bigdubs Nov. 12 at 8:21 PM

$NBY I trust my extensive DD now just waiting for the pump

0 · Reply

Bigdubs Nov. 8 at 1:09 AM

$NBY From the new 10Q: "As part of its broader capital allocation review, the Company has begun evaluating opportunities within emerging financial infrastructure and network-based markets. These opportunities may include select blockchain-based assets that the Company believes could enhance capital efficiency and long-term stockholder value." https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319562782&type=HTML&symbol=NBY&cdn=3f2278c95d71f80fa72b8167138d825c&companyName=NovaBay+Pharmaceuticals+Inc.&formType=10-Q&formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&dateFiled=2025-11-07

0 · Reply

Bigdubs Nov. 6 at 6:43 PM

$NBY just hovering around the prefunded warrant price. Done more DD. The terms of the funding need to be in place before any major pump. They are trying to raise up to 200m dollars on the last S-3 but have no vehicle to do it yet. That will need to be in place. I also expect a nothing burger 10Q to be released shortly.

0 · Reply

SPYmyQQQ Nov. 5 at 9:03 PM

🚀 New Signal ✅ 💊 $NBY 🗓️ Nov 5, 2025 💵 Entry: $1.10 🎯 Target (Opt.): $1.30 (+18.18%) 👉 FREE TRIAL! Check bio.

0 · Reply

Bigdubs Nov. 3 at 8:48 PM

$NBY With the company pivot coming very soon here are my thoughts: Pros: This moons on a Crypto/Fintech announcement. Did DD on Kazley the new CEO and he's a crypto market plumbing with a fintech tilt. With the new share float limit a crypto ETF is possible (although slim) he did try it once. Risks: R/S before the plan is announced or unnecessary dilution not giving it a pump. Timing: Very Soon we should know more

0 · Reply

JL_TradeZ Nov. 3 at 2:30 AM

4-Month Special Play Recap 🔥 Crazy stretch the last few months. From July to October we caught over 30 special plays with some massive runs $NBY +566%, $HUDI +366%, $AIHS +310%, $AQMS +426%, $NDRA +222% and plenty more to name a few. The goal’s always been to stay consistent, track momentum early, and find clean setups before the crowd. Going to keep doing my best to spot and track more solid special plays for the team as we head into November 💪

1 · Reply

LosingItallday Oct. 31 at 4:47 PM

$NBY

0 · Reply

Kingcrab3333 Oct. 31 at 4:24 PM

$NBY

0 · Reply

Bigdubs Oct. 31 at 3:30 PM

$NBY by EOD the new owners take over. Gonna be a huge filing drop soon.

1 · Reply

J0rdsz Oct. 31 at 2:05 AM

$NBY

0 · Reply

NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

Sep 18, 2025, 4:30 PM EDT - 2 months ago

NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

Aug 26, 2025, 4:05 PM EDT - 2 months ago

NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

Aug 19, 2025, 5:25 PM EDT - 3 months ago

NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Mar 7, 2025, 6:50 AM EST - 9 months ago

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

Jan 23, 2025, 8:00 AM EST - 10 months ago

NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

Dec 19, 2024, 6:50 AM EST - 11 months ago

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

Dec 9, 2024, 6:50 AM EST - 1 year ago

NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

Nov 22, 2024, 4:05 PM EST - 1 year ago

NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

Nov 15, 2024, 8:00 AM EST - 1 year ago

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand

Nov 7, 2024, 4:05 PM EST - 1 year ago

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

Oct 29, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals

Sep 20, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets

Aug 13, 2024, 11:29 PM EDT - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

Jul 30, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales

Jul 29, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option

Jul 26, 2024, 8:30 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering

Jul 16, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day

Jul 11, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million

Jul 1, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

Jun 28, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions

Jun 7, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American

May 29, 2024, 5:22 PM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates

May 13, 2024, 8:30 AM EDT - 1 year ago

NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms

May 11, 2024, 1:59 PM EDT - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

May 7, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon

May 3, 2024, 6:50 AM EDT - 1 year ago

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

Apr 22, 2024, 6:57 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales

Apr 19, 2024, 6:00 PM EDT - 1 year ago

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity

Apr 17, 2024, 6:59 AM EDT - 1 year ago

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

Mar 26, 2024, 6:43 PM EDT - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:05 PM EDT - 1 year ago

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Mar 25, 2024, 6:38 PM EDT - 1 year ago

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024

Mar 14, 2024, 8:00 AM EDT - 1 year ago

NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023

Jan 30, 2024, 9:00 AM EST - 1 year ago

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

Jan 9, 2024, 9:15 AM EST - 2 years ago

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network

SNOA

Dec 6, 2023, 6:50 AM EST - 2 years ago

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

Nov 9, 2023, 11:43 PM EST - 2 years ago

NovaBay Pharmaceuticals, Inc. (NBY) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 2 years ago

NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

Nov 2, 2023, 6:50 AM EDT - 2 years ago

NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

Oct 11, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

Oct 2, 2023, 6:50 AM EDT - 2 years ago

NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

Sep 14, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

Sep 11, 2023, 8:00 AM EDT - 2 years ago

NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

Bigdubs Nov. 12 at 8:21 PM

$NBY I trust my extensive DD now just waiting for the pump

0 · Reply

Bigdubs Nov. 8 at 1:09 AM

0 · Reply

Bigdubs Nov. 6 at 6:43 PM

0 · Reply

SPYmyQQQ Nov. 5 at 9:03 PM

🚀 New Signal ✅ 💊 $NBY 🗓️ Nov 5, 2025 💵 Entry: $1.10 🎯 Target (Opt.): $1.30 (+18.18%) 👉 FREE TRIAL! Check bio.

0 · Reply

Bigdubs Nov. 3 at 8:48 PM

0 · Reply

JL_TradeZ Nov. 3 at 2:30 AM

1 · Reply

LosingItallday Oct. 31 at 4:47 PM

$NBY

0 · Reply

Kingcrab3333 Oct. 31 at 4:24 PM

$NBY

0 · Reply

Bigdubs Oct. 31 at 3:30 PM

$NBY by EOD the new owners take over. Gonna be a huge filing drop soon.

1 · Reply

J0rdsz Oct. 31 at 2:05 AM

$NBY

0 · Reply

Stock_Catcher Oct. 31 at 1:25 AM

New Video Out Just Now on Bullish Analysis on $SLDP $NBY $EDHL $TENX $VYNE and many more stocks that can rip! https://www.youtube.com/watch?v=maPONE9HF1s

1 · Reply

_Blaze318 Oct. 28 at 7:45 PM

$NBY waiting on $2

0 · Reply

Bigdubs Oct. 28 at 6:01 AM

$NBY apparently not many know this will become a crypto play. As I learned before last pump the Divvy was already told in the fillings and you all let me buy at .89… looking forward to sell on some non filing readers when they chase. November should be fun!

0 · Reply

CashTopic Oct. 23 at 3:16 PM

$NBY in a nutshell, R01/Framework is in control of almost 57 million shares of NBY common shares.

0 · Reply

CashTopic Oct. 23 at 3:15 PM

$NBY per Stock Titan 👇

0 · Reply

CashTopic Oct. 23 at 2:25 PM

$NBY I earlier posted part of an article listing new titles for CEO, VP and Financial Officer. It states that NBY products include NeutroPhase and its counterpart as a proprietary interest. The NBY sight lists PhaseOne and Avenova as their own products... Has Avenova been reintroduced to NBY? Not officially...

0 · Reply

CashTopic Oct. 23 at 2:16 PM

$NBY Framework is involved with management of crypto investment and raising capital in mass quantities from what I have read about them. They manage over a billion in assets and have raised over 100 million in funds. What they are doing with little ole NBY is a perplexity to me. Especially considering that they approved an RS for this ticker but, did not approve the issuance of any additional preferred shares. I've gotta read more about this.

0 · Reply

CashTopic Oct. 23 at 1:07 PM

$NBY received compliance letter from NYSE and changes leadership on the same day basically. I have been trying to get caught up with every detail of Framework and associates. These guys are different. And, I'd like to know more about previous NBY board members resigning.

0 · Reply

CashTopic Oct. 23 at 1:03 PM

$NBY

0 · Reply

CashTopic Oct. 23 at 12:40 PM

$NBY

0 · Reply

XaviersLessons Oct. 23 at 7:01 AM

$TERN $HCTI $GYRE $NBY How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI

0 · Reply

BillionerOfKing Oct. 22 at 4:16 PM

$NBY Current Stock Price: $1.11 No options data available.

0 · Reply

Market Cap	6.49M
Revenue (ttm)	9.78M
Net Income (ttm)	-7.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-73.82%
Debt to Equity Ratio	0.00

Volume	59,712
Avg Vol	917,184
Day's Range	N/A - N/A
Shares Out	6.01M
Stochastic %K	75%
Beta	0.58
Analysts	Sell
Price Target	$0.85